SecSonar.com

Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Arbutus Biopharma Corporation (ABUS) is a Biotechnology company based in US with a market capitalization of $922.5M. Revenue grew 128.2% year-over-year and free cash flow was negative at -$39.6M. This page tracks ABUS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 44 employees · IPO Jul 26, 2007

Valuation

Valuation & price

$4.35 · as of May 15, 2026 · -12.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

12.05

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.90$4.02$3.13Jul 25Dec 25Jul 26Jul 7, 25$3.14Jul 9, 25$3.34Jul 11, 25$3.17Jul 15, 25$3.13Jul 17, 25$3.14Jul 21, 25$3.14Jul 23, 25$3.23Jul 25, 25$3.22Jul 29, 25$3.30Jul 31, 25$3.28Aug 4, 25$3.34Aug 6, 25$3.47Aug 11, 25$3.35Aug 13, 25$3.37Aug 15, 25$3.37Aug 19, 25$3.49Aug 21, 25$3.58Aug 25, 25$3.50Aug 27, 25$3.65Aug 29, 25$3.71Sep 3, 25$3.93Sep 5, 25$4.20Sep 9, 25$4.33Sep 11, 25$4.90Sep 16, 25$4.40Sep 18, 25$4.42Sep 22, 25$4.43Sep 24, 25$4.49Sep 26, 25$4.41Sep 30, 25$4.54Oct 2, 25$4.49Oct 6, 25$4.34Oct 8, 25$4.18Oct 10, 25$4.11Oct 14, 25$4.24Oct 16, 25$4.51Oct 21, 25$4.48Oct 23, 25$4.28Oct 27, 25$4.47Oct 29, 25$4.61Oct 31, 25$4.73Nov 4, 25$4.50Nov 6, 25$4.44Nov 10, 25$4.59Nov 12, 25$4.84Nov 14, 25$4.52Nov 18, 25$4.45Nov 20, 25$4.20Nov 25, 25$4.32Nov 28, 25$4.41Dec 2, 25$4.17Dec 4, 25$4.41Dec 8, 25$4.52Dec 10, 25$4.59Dec 12, 25$4.71Dec 16, 25$4.59Dec 18, 25$4.54Dec 22, 25$4.72Dec 24, 25$4.79Dec 29, 25$4.72Jan 2, 26$4.77Jan 6, 26$4.79Jan 8, 26$4.65Jan 12, 26$4.50Jan 14, 26$4.78Jan 16, 26$4.06Jan 21, 26$4.14Jan 23, 26$4.06Jan 27, 26$4.16Jan 29, 26$4.13Feb 2, 26$4.39Feb 4, 26$3.88Feb 9, 26$4.05Feb 11, 26$4.16Feb 13, 26$3.98Feb 18, 26$4.13Feb 20, 26$4.27Feb 24, 26$4.46Feb 26, 26$4.70Mar 2, 26$4.67Mar 4, 26$4.75Mar 6, 26$4.53Mar 10, 26$4.71Mar 12, 26$4.32Mar 17, 26$4.36Mar 19, 26$4.37Mar 23, 26$4.42Mar 25, 26$4.53Mar 27, 26$4.29Mar 31, 26$4.50Apr 2, 26$4.48Apr 7, 26$4.46Apr 9, 26$4.30Apr 13, 26$4.37Apr 15, 26$4.48Apr 17, 26$4.72Apr 22, 26$4.43Apr 24, 26$4.20Apr 28, 26$4.15Apr 30, 26$4.20May 4, 26$4.39May 6, 26$4.42May 8, 26$4.34May 12, 26$4.31May 14, 26$4.35May 18, 26$4.17May 20, 26$4.37May 22, 26$4.35May 28, 26$4.60Jun 1, 26$4.48Jun 3, 26$4.35Jun 5, 26$4.25Jun 9, 26$4.25Jun 11, 26$4.29Jun 15, 26$4.32Jun 17, 26$4.43Jun 22, 26$4.52Jun 24, 26$4.46Jun 26, 26$4.58Jul 2, 26$4.87
$3.1352-week range$4.95
Loading valuation history…

Fundamentals

Key fundamentals

$922.5M

Market cap

128.2%

Revenue growth (YoY)

97.4%

Gross margin

-$39.6M

Free cash flow (USD)

-$87.3M

Net debt

Net cash position

3.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.5MFY 2017$10.7MFY 2018$5.9MFY 2019$6.0MFY 2020$6.9MFY 2021$11.0MFY 2022$39.0MFY 2023$18.1MFY 2024$6.2MFY 2025$14.1M
$1.5M$14.1M

Free cash flow by year

2016 → 2025

FY 2016$-61.9MFY 2017$-55.9MFY 2018$-69.0MFY 2019$-71.6MFY 2020$-51.7MFY 2021$-68.3MFY 2022$-35.9MFY 2023$-86.9MFY 2024$-65.0MFY 2025$-39.6M
-$61.9M-$39.6M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202597.4%
100.0%97.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventIncentive Plan EstablishedMay 27, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventFDA Fast Track DesignationApr 15, 2026Filing

Questions

Frequently asked questions

What is Arbutus Biopharma Corporation's market cap?

Arbutus Biopharma Corporation (ABUS) has a market capitalization of $922.5M.

What is ABUS's P/E ratio?

A meaningful P/E ratio is not available for ABUS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ABUS's price-to-book (P/B) ratio?

ABUS trades at 12.05 times book value per share.

Are insiders buying ABUS stock?

SEC Form 4 filings show no open-market insider buys at Arbutus Biopharma Corporation in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

SPRY

ARS Pharmaceuticals, Inc.

$908.6M

PHAR

Pharming Group N.V.

$942.8M

KURA

Kura Oncology, Inc.

$900.2M

JANX

Janux Therapeutics, Inc.

$894.3M

XNCR

Xencor, Inc.

$885.3M

MGTX

MeiraGTx Holdings plc

$962.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.